nach oben

Inflammation

Erschienen in:

01.06.2015

The Roles of Egr-2 in Autoimmune Diseases

verfasst von: Min Zhang, Ying Wang, Jian-Shu Wang, Jiao Liu, Meng-Meng Liu, Hai-Bing Yang

Erschienen in: Inflammation | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Being a member of the early growth response (Egr) family of transcription factors, Egr-2 is expressed in a variety of cell types of the immune system. Recent findings imply that Egr-2 is important in the development and function of T helper (Th) 17 cell, regulatory T (Treg) cell, as well as dendritic cell (DC). Although these cells perform significantly in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus, multiple sclerosis, and systemic sclerosis, the roles of Egr-2 in the pathogenesis of autoimmune diseases can not be neglected. In this article, we will discuss recent findings about the important roles of Egr-2 in immune cells and the possible pathological roles of Egr-2 in autoimmune diseases.

O’Donovan, K.J., W.G. Tourtellotte, J. Millbrandt, and J.M. Baraban. 1999. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends in Neurosciences 22: 167–173.CrossRefPubMed

Le, N., R. Nagarajan, J.Y. Wang, J. Svaren, C. LaPash, T. Araki, R.E. et al. 2005. Nab proteins are essential for peripheral nervous system myelination. Nauret Neuroscience 8: 932–940.

Tourtellotte, W.G., C. Keller-Peck, J. Milbrandt, and J. Kucera. 2001. The transcription factor Egr3 modulates sensory axon-myotube interactions during muscle spindle morphogenesis. Developmental Biology 232: 388–399.CrossRefPubMed

Yang, S.Z., I.A. Eltoum, and S.A. Abdulkadir. 2006. Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen-depleted environment. Journal of Cellular Biochemistry 97: 1292–1299.CrossRefPubMed

Schnell, F.J., A.L. Zoller, S.R. Patel, I.R. Williams, and G.J. Kersh. 2006. Early growth response gene 1 provides negative feedback to inhibit entry of progenitor cells into the thymus. Journal of Immunology 176: 4740–4747.CrossRef

Miyazaki, T., and F.A. Lemonnier. 1998. Modulation of thymic selection by expression of an immediate-early gene, early growth response 1 (Egr-1). Journal of Experimental Medicine 188: 715–723.CrossRefPubMedCentralPubMed

Laslo, P., C.J. Spooner, A. Warmflash, D.W. Lancki, H.J. Lee, R. Sciammas, et al. 2006. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 126: 755–766.CrossRefPubMed

Fang, F., K. Ooka, S. Bhattacharyya, J. Wei, M. Wu, P. Du, et al. 2011. The early growth response gene Egr-2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. American Journal of Pathology 178: 2077–2090.CrossRefPubMedCentralPubMed

Keeton, A.B.., K.D. Bortoff, W.L. Bennett, J.L. Franklin, D.Y. Venable, and J.L. Messina. 2013. Insulin-regulated expression of Egr-1 and Krox20: dependence on ERK1/2 and interaction with p38 and PI3-kinase pathways. Endocrinology 144: 5402–5410.CrossRef

10.

Schneider-Maunoury, S., P. Topilko, T. Seitandou, G. Levi, M. Cohen-Tannoudji, S. Pournin, et al. 1993. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain. Cell 75: 1199–1214.CrossRefPubMed

11.

Swiatek, P.J., and T. Gridley. 1993. Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. Genes and Development 7: 2071–2084.CrossRefPubMed

12.

Jang, S.W., R. Srinivasan, E.A. Jones, G. Sun, S. Keles, C. Krueger, et al. Locus-wide identification of Egr-2/Krox20 regulatory targets in myelin genes. Journal of Neurochemistry 115: 1409–1420.

13.

Okamura, T., K. Fujio, M. Shibuya, S. Sumitomo, H. Shoda, S. Sakaguchi, et al. 2009. CD4+CD25-LAG3+regulatory T cells controlled by the transcription factor Egr-2. Proceedings of the National Academy of Sciences of the United States of America 106: 13974–13979.CrossRefPubMedCentralPubMed

14.

Miao, T., M. Raymond, P. Bhullar, E. Ghaffari, A.L. Symonds, U.C. Meier, et al. 2013. Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf. Journal of Immunology 190: 58–65.CrossRef

15.

Miah, M.A., S.E. Byeon, M.S. Ahmed, C.H. Yoon, S.J. Ha, and Y.S. Bae. 2013. Egr-2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity. European Journal of Immunology 43: 2484–2496.CrossRefPubMed

16.

Lauritsen, J.P., S. Kurella, S.Y. Lee, J.M. Lefebvre, M. Rhodes, J. Alberola-Ila, et al. 2008. Egr-2 is required for Bcl-2 induction during positive selection. Journal of Immunology 181: 7778–7785.CrossRef

17.

Collins, S., M.A. Lutz, P.E. Zarek, R.A. Anders, G.J. Kersh, and J.D. Powell. 2008. Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. European Journal of Immunology 38: 528–536.CrossRefPubMedCentralPubMed

18.

Safford, M., S. Collins, M.A. Lutz, A. Allen, C.T. Huang, J. Kowalski, et al. 2005. Egr-2 and Egr-3 are negative regulators of T cell activation. Nature Immunology 6: 472–480.CrossRefPubMed

19.

Zhu, B., A.L. Symonds, J.E. Martin, D. Kioussis, D.C. Wraith, S. Li, et al. 2008. Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. Journal of Experimental Medicine 205: 2295–2307.CrossRefPubMedCentralPubMed

20.

Li, S., T. Miao, M. Sebastian, P. Bhullar, E. Ghaffari, M. Liu, et al. 2012. The transcription factors Egr-2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. Immunity 37: 685–696.CrossRefPubMedCentralPubMed

21.

Schraml, B.U., K. Hildner, W. Ise, W.L. Lee, W.A. Smith, B. Solomon, et al. 2009. The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature 460: 405–409.PubMedCentralPubMed

22.

Groux, H., A. O’Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. de Vries, et al. 1997. A CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737–742.CrossRefPubMed

23.

Workman, C.J., and D.A. Vignali. 2003. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. European Journal of Immunology 33: 970–979.CrossRefPubMed

24.

Workman, C.J., L.S. Cauley, I.J. Kim, M.A. Blackman, D.L. Woodland, and D.A. Vignali. 2004. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. Journal of Immunology 172: 5450–5455.CrossRef

25.

Huang, C.T., C.J. Workman, D. Flies, X. Pan, A.L. Marson, G. Zhou, et al. 2004. Role of LAG-3 in regulatory T cells. Immunity 21: 503–513.CrossRefPubMed

26.

Workman, C.J., D.S. Rice, K.J. Dugger, C. Kurschner, and D.A. Vignali. 2002. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). European Journal of Immunology 32: 2255–2263.CrossRefPubMed

27.

Harris, J.E., K.D. Bishop, N.E. Phillips, J.P. Mordes, D.L. Greiner, A.A. Rossini, et al. 2004. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. Journal of Immunology 173: 7331–7338.CrossRef

28.

Okamura, T., K. Fujio, S. Sumitomo, and K. Yamamoto. 2012. Roles of LAG3 and EGR-2 in regulatory T cells. Annals of the Rheumatic Diseases 71(Suppl 2): i96–i100.CrossRefPubMed

29.

Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Journal of Experimental Medicine 179: 1109–1118.CrossRefPubMed

30.

Platt, C.D., J.K. Ma, C. Chalouni, M. Ebersold, H. Bou-Reslan, R.A. Carano, et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proceedings of the National Academy of Sciences USA 107: 4287–4292.

31.

Evel-Kabler, K., X.T. Song, M. Aldrich, X.F. Huang, and S.Y. Chen. 2006. SOCS1 restricts dendritic cells’ ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. Journal of Clinical Investigation 116: 90–100.CrossRefPubMedCentralPubMed

32.

Li, B.Z., Q.L. Ye, W.D. Xu, J.H. Li, D.Q. Ye, and Y. Xu. 2013. GM-CSF alters dendritic cells in autoimmune diseases. Autoimmunity 46: 409–418.CrossRefPubMed

33.

Pan, H.F., D.Q. Ye, and X.P. Li. 2008. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nature Clinical Practice Rheumatology 4: 352–353.PubMed

34.

Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661–678.CrossRef

35.

Rioux, J.D., R.J. Xavier, K.D. Taylor, M.S. Silverberg, P. Goyette, A. Huett, et al. 2007. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genetics 39: 596–604.CrossRefPubMedCentralPubMed

36.

Myouzen, K., Y. Kochi, K. Shimane, K. Fujio, T. Okamura, Y. Okada, et al. 2010. Regulatory polymorphisms in EGR-2 are associated with susceptibility to systemic lupus erythematosus. Human Molecular Genetics 19: 2313–2320.CrossRefPubMed

37.

International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, S. Sawcer, G. Hellenthal, M. Pirinen, C.C. Spencer, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.CrossRef

38.

Vandenbroeck, K., J. Alvarez, B. Swaminathan, I. Alloza, F. Matesanz, E. Urcelay, et al. 2012. A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes and Immunity 13: 21–28.CrossRefPubMed

39.

Beyeen, A.D., M.Z. Adzemovic, J. Ockinger, P. Stridh, K. Becanovic, H. Laaksonen, et al. 2010. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. Journal of Immunology 185: 6883–6890.CrossRef

40.

Mayes, M.D. 2012. The genetics of scleroderma: looking into the postgenomic era. Current Opinion in Rheumatology 24: 677–684.CrossRefPubMedCentralPubMed

41.

Allanore, Y., M. Saad, P. Dieudé, J. Avouac, J.H. Distler, P. Amouyel, et al. 2011. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genetics 7: e1002091.CrossRefPubMedCentralPubMed

42.

Koumakis, E., M. Bouaziz, P. Dieudé, B. Ruiz, G. Riemekasten, P. Airo, et al. 2013. A regulatory variant in CCR6 is associated with anti-topoisomerase positive systemic sclerosis susceptibility. Arthritis and Rheumatism 65: 3202–3208.CrossRefPubMed

43.

Varga, J., and B. Pasche. 2008. Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Current Opinion in Rheumatology 20: 720–728.CrossRefPubMed

44.

Heldin, C.H., M. Landstrom, and A. Moustakas. 2009. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Current Opinion in Cell Biology 21: 166–176.CrossRefPubMed

45.

Qiu, F., L. Song, N. Yang, and X. Li. 2013. Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus 22: 1011–1016.CrossRefPubMed

Titel: The Roles of Egr-2 in Autoimmune Diseases
verfasst von: Min Zhang
Ying Wang
Jian-Shu Wang
Jiao Liu
Meng-Meng Liu
Hai-Bing Yang
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 3/2015
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-014-0059-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The Roles of Egr-2 in Autoimmune Diseases

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

In Vitro Oxidation of Fibrinogen Promotes Functional Alterations and Formation of Advanced Oxidation Protein Products, an Inflammation Mediator

Mesenteric Lymph Duct Drainage Attenuates Acute Lung Injury in Rats with Severe Intraperitoneal Infection

Trichostatin A Protects Against Experimental Acute-on-Chronic Liver Failure in Rats Through Regulating the Acetylation of Nuclear Factor-κB

Supplemental Carvacrol Can Reduce the Severity of Inflammation by Influencing the Production of Mediators of Inflammation

The Effects of Cordycepin on Ovalbumin-Induced Allergic Inflammation by Strengthening Treg Response and Suppressing Th17 Responses in Ovalbumin-Sensitized Mice

Selenium Deficiency Facilitates Inflammation Through the Regulation of TLR4 and TLR4-Related Signaling Pathways in the Mice Uterus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin